Loading clinical trials...
Loading clinical trials...
This study is to assess noninferiority in efficacy and to assess overall safety of CT P13 compared to Remicade in patients with active Crohn's disease up to Week 54.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Celltrion
Collaborators
NCT06226883 · Inflammatory Bowel Diseases, Crohn's Disease
NCT07184931 · Crohn's Disease
NCT06918808 · Perianal Fistula Due to Crohn's Disease
NCT06647615 · Crohn's Disease, Abdominal Pain (AP)
NCT07377188 · IBD, Crohn's Disease, and more
Nashville Medical Research Institute
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions